Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22317760.
- Also identified by DOI 10.1158/1078-0432.CCR-11-3282 and PMC identifier 3329215.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors. The finding that exon 19 insertion mutations are also sensitive to this class of drugs suggests that testing for these mutations should be done and that these patients will benefit from treatment with tyrosine kinase inhibitors.
Medical subject headings
- Adenocarcinoma
- ErbB Receptors
- Lung Neoplasms
- Mutagenesis, Insertional